Based on the Sangamo Therapeutics Inc. stock forecasts from 3 analysts, the average analyst target price for Sangamo Therapeutics Inc. is USD 11.67 over the next 12 months. Sangamo Therapeutics Inc.’s average analyst rating is Hold. Stock Target Advisor’s own stock analysis of Sangamo Therapeutics Inc. is Bearish, which is based on 1 positive signal and 4 negative signals. At the last closing, Sangamo Therapeutics Inc.’s stock price was USD 4.14. Sangamo Therapeutics Inc.’s stock price has changed by -0.01% over the past week, -1.55% over the past month and -60.72% over the last year.
Wedbush just recently reiterated it’s Neutral rating on the stock. The analyst has a unchanged target of $10 on the stock
As a clinical-stage biotechnology firm, Sangamo Therapeutics Inc. develops genomic therapies that improve patients’ lives through gene therapy, cell therapy, genome editing, and gene regulation. Sangamo BioSciences, Inc. became Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is based in Brisbane.
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What we don’t like:
Poor risk-adjusted returns
This company is delivering below median risk-adjusted returns to its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Negative cash flow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector.